Exploring how receptor activation affects cancer cell behavior
Understanding how receptor tyrosine kinase activation dynamics specify proliferative cellular responses
This study is looking at how certain proteins in cancer cells can change their behavior when activated, which could help us find new ways to treat cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10849874 on NIH RePORTER |
What this research studies
This research investigates how the activation of receptor tyrosine kinases (RTKs), which are important targets in cancer therapy, influences the behavior and fate of cancer cells. By using advanced imaging and biochemical techniques, the study aims to understand how different ligands can lead to distinct cellular responses, such as proliferation or differentiation. The researchers will analyze the dynamics of signaling pathways activated by RTKs to uncover the mechanisms behind these responses, which could lead to new treatment strategies for cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that involve receptor tyrosine kinases and who may benefit from novel therapeutic approaches.
Not a fit: Patients with cancers not driven by receptor tyrosine kinases or those who are not eligible for new treatment strategies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies by providing insights into how to overcome resistance to current treatments.
How similar studies have performed: Previous research has shown promising results in understanding RTK signaling dynamics, suggesting that this approach could yield valuable insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Lemmon, Mark a — Yale University
- Study coordinator: Lemmon, Mark a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.